Ignite Creation Date:
2025-12-24 @ 3:23 PM
Ignite Modification Date:
2026-04-17 @ 9:03 AM
Study NCT ID:
NCT02139592
Status:
COMPLETED
Last Update Posted:
2020-07-13
First Post:
2014-04-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Sponsor:
Takeda
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-04-17
Start Date Type:
ACTUAL
Primary Completion Date:
2017-06-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-06-30
Completion Date Type:
ACTUAL
First Submit Date:
2014-04-17
First Submit QC Date:
None
Study First Post Date:
2014-05-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-06-25
Results First Submit QC Date:
None
Results First Post Date:
2019-05-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-06-25
Last Update Post Date:
2020-07-13
Last Update Post Date Type:
ACTUAL